Science is Beautiful Blog

Biosimilars: High on Obama’s Agenda

Posted by John Kouten, CEO

Jun 19, 2009 4:39:00 PM

Where is legislation on biosimilars heading?  How will this impact innovator biopharmaceutical and biotechnology companies?  What is your position on the issue? 

Please read my primer on the coming storm of biosimilars published in this month’s Pharmaceutical Executive.

This piece provides a summary overview of the situation and communication strategies to help innovator companies prepare and communicate around this issue.

-- John Kouten 

Topics: US pharmaceutical market, biotechnology and medical technology companies, biosimilars


Most Popular

Recent Posts

Posts by tags

see all